FirstTake on Pharma - Pharma News and Analysis Podcast podcast

The FirstTake Podcast – Gilead’s oncology strategy under the spotlight

0:00
15:40
Manda indietro di 15 secondi
Manda avanti di 15 secondi
On this week’s episode FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss why Gilead is getting flak for a positive cancer drug study, what’s gone wrong at bluebird bio and why the FDA has been so quick to expand approval of Bristol Myers Squibb’s Opdivo for the treatment of neoadjuvant lung cancer.

Altri episodi di "FirstTake on Pharma - Pharma News and Analysis Podcast"